Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study
Drug and Alcohol Review · 2023-05 · 42 (4) · 791-802
DOI: 10.1111/dar.13616 ↗At a glance
Journal article in Drug and Alcohol Review, published online on 2023-02-14. Written by Eve Allen and 4 co-authors. Institution: UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia. Major MEDLINE topics: Buprenorphine, Opioid-Related Disorders. Cited 22 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Introduction
The introduction of depot buprenorphine for the treatment of opioid dependence allows for reduced dosing frequency compared with conventional treatments, such as oral methadone and sublingual buprenorphine‐naloxone. Reduced dosing frequency is perceived to reduce issues such as high out‐of‐pocket costs, frequent attendance to pharmacies, stigmatisation and the risk of diversion for unsanctioned opioid use. This study aims to explore the experiences of patients receiving depot buprenorphine from an Australian publicly operated drug and alcohol service.
Methods
Participants were recruited from the service over a 5‐week period in 2021. Twenty‐eight participants consented to be involved in a mixed methods quantitative verbal survey and qualitative interview process.
Results
The majority of participants reported satisfaction with depot buprenorphine across the domains of efficacy, convenience and global satisfaction. Participants perceived benefits as increased convenience, reduced stigmatisation and the inability to ‘skip’ daily Medication Assisted Treatment for Opioid Dependence (MATOD) doses. There were mixed experiences with the ability for depot buprenorphine to ‘hold’ participants throughout the dosing interval. Reduced contact and disconnection from healthcare services were reported as an issue for some participants when initiating depot buprenorphine. Discussion and Conclusions Patient perceptions of depot buprenorphine appear to be deeply rooted in prior experience with ‘conventional’ MATOD treatments. Depot buprenorphine is seen to be beneficial socially, personally, and financially by the majority of patients interviewed. The potential for disconnection from services and mixed experiences of efficacy throughout the dosing period may negatively influence patient experience.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
- Drug and Alcohol Services South Australia, SA Health, Adelaide, Australia.
- SA Pharmacy, Statewide Clinical Support Services, SA Health, Adelaide, Australia.
ORCID profiles: Eve Allen
Cite
APA
Allen, E., Samadian, S., Altobelli, G., Johnson, J., & Holmwood, C. (2023). Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study. Drug and Alcohol Review, 42(4), 791-802. https://doi.org/10.1111/dar.13616
Vancouver
Allen E, Samadian S, Altobelli G, Johnson J, Holmwood C. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study. Drug and Alcohol Review. 2023;42(4):791-802. doi:10.1111/dar.13616
BibTeX
@article{Allen2023,
author = {Allen, Eve and Samadian, Sona and Altobelli, Gary and Johnson, Jacinta and Holmwood, Chris},
title = {Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed‐methods study},
journal = {Drug and Alcohol Review},
year = {2023},
volume = {42},
number = {4},
pages = {791--802},
doi = {10.1111/dar.13616}
}
EUVIMED